tirzepatide for the treatment of obstructive sleep apnea and obesity Which Patients Benefit Most from & OSA? Trizepatide journal club presentation.ppt

However, results are estimates, and they are for informational purposes only, not a replacement for medical advice or as a self-diagnosis tool

Hepatic Lipid Metabolism Researchers studying NAFLD and MASH models have examined retatrutide's effect on hepatic triglyceride content, where glucagon-receptor agonism is hypothesized to drive intrahepatic lipid mobilization beyond what GLP-1 alone produces

Sources Eli Lilly press release: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

Further research is warranted to evaluate the impact of this intervention model on patient outcomes

You might be wondering why I dont tell you to go out and grab yourself some Ozempic if GLP-1 agonists are so great at helping folks lose weight